These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30217639)

  • 21. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
    Liang Y; Wakelee HA; Neal JW
    Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
    Shepherd FA; Domerg C; Hainaut P; Jänne PA; Pignon JP; Graziano S; Douillard JY; Brambilla E; Le Chevalier T; Seymour L; Bourredjem A; Le Teuff G; Pirker R; Filipits M; Rosell R; Kratzke R; Bandarchi B; Ma X; Capelletti M; Soria JC; Tsao MS
    J Clin Oncol; 2013 Jun; 31(17):2173-81. PubMed ID: 23630215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
    Iams WT; Yu H; Shyr Y; Patil T; Horn L; McCoach C; Kelly K; Doebele RC; Camidge DR
    Clin Lung Cancer; 2018 Nov; 19(6):531-543. PubMed ID: 30197261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
    Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
    Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
    Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
    Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.
    Cuffe S; Bourredjem A; Graziano S; Pignon JP; Domerg C; Ezzalfani M; Seymour L; Strevel E; Burkes R; Capelletti M; Jänne PA; Tsao MS; Shepherd FA
    J Thorac Oncol; 2012 Jun; 7(6):963-72. PubMed ID: 22588152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.
    Zhang Y; Fang W; Yan Y; Wang M; Kang S; Sheng J; Zhan J; Chen N; Hong S; Yang Y; Ma Y; He D; Qin T; Zhou T; Tang Y; He X; Liang W; Zhang L
    Med Oncol; 2015 Mar; 32(3):61. PubMed ID: 25663066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
    Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
    Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
    Froesch P; Mark M; Rothschild SI; Li Q; Godar G; Rusterholz C; Oppliger Leibundgut E; Schmid S; Colombo I; Metaxas Y; König D; Sessa C; Gautschi O; Früh M;
    Lung Cancer; 2021 Jun; 156():91-99. PubMed ID: 33933896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
    Jänne PA; Smith I; McWalter G; Mann H; Dougherty B; Walker J; Orr MC; Hodgson DR; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios CH; Franke FA; Crinò L; Smith P
    Br J Cancer; 2015 Jul; 113(2):199-203. PubMed ID: 26125448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
    Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
    Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
    Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
    Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
    Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
    Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.